Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea's Health Minister In U.S. To Sign MOU, Promote Korean Generics And Universal Coverage

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Minister of Health, Welfare and Family Affairs Jeon Jae-Hee and U.S. Department of Health and Human Services Secretary Kathleen Sebelius signed a memorandum of understanding in Washington July 14 on bilateral cooperation in the fight against pandemic influenza

You may also be interested in...



S Korean President Pushes Pharma Deals In Mideast Swing

While the South Korean pharma sector is ultimately targeting U.S. and European markets in its longer-term expansion drive, it is for now trying to build up wider relations with Middle East countries with a little top-level political help.

OECD Recommends Changes in Korea's Healthcare System In Its First Survey Of Korea's Pharma Sector

SEOUL - OECD has recommended a set of changes - some of them already pursued by the South Korean government - to get South Korea's healthcare system working more efficiently to curtail rapid increases in healthcare spending

OECD Recommends Changes in Korea's Healthcare System In Its First Survey Of Korea's Pharma Sector

SEOUL - OECD has recommended a set of changes - some of them already pursued by the South Korean government - to get South Korea's healthcare system working more efficiently to curtail rapid increases in healthcare spending

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel